Skip to content
-
Subscribe to our newsletter & never miss our best posts. Subscribe Now!
Today's News. Tomorrow's Perspective. Today's News. Tomorrow's Perspective.

Deliver fast, factual, and easy-to-understand news covering global events, technology, business, science, AI, health, entertainment, and lifestyle.

Today's News. Tomorrow's Perspective. Today's News. Tomorrow's Perspective.

Deliver fast, factual, and easy-to-understand news covering global events, technology, business, science, AI, health, entertainment, and lifestyle.

  • Home
  • Breaking News
  • Business
  • Sports
  • Health
  • Politics
  • Technology & AI
  • World
  • Home
  • Breaking News
  • Business
  • Sports
  • Health
  • Politics
  • Technology & AI
  • World
Close

Search

Subscribe
Johnson & Johnson seeks to buy eye disease biotech for up to $3.4 billion
Business

Johnson & Johnson seeks to buy eye disease biotech for up to $3.4 billion

jack colman
By jack colman
November 16, 2026 2 Min Read
Comments Off on Johnson & Johnson seeks to buy eye disease biotech for up to $3.4 billion

Unlock Editor’s Digest for free

Roula Khalaf, editor-in-chief of the FT, selects her favorite stories in this weekly newsletter.

Johnson & Johnson is set to buy a private developer of eye disease drugs for up to $3.4 billion, the latest in a series of targeted acquisitions in the biotechnology sector.

The New Jersey-based pharmaceutical maker could announce a deal to buy Ollin Biosciences as soon as Monday, according to people familiar with the matter.

Under the terms of the deal under discussion, J&J could pay Ollin’s backers $2.2 billion in cash upfront and an additional $1.2 billion in potential milestone payments, the sources added. However, they warned that the negotiations could still fail.

Ollin, backed by investment firms Arch Venture Partners and Mubadala Capital, is developing a drug to treat two major causes of severe vision loss later in life.

The potential deal comes as the pharmaceutical industry prepares to head to London this week for the annual Jefferies Healthcare Summit, a marquee gathering of executives, investors and advisors.

A record 46 biotechs valued at more than $1 billion have been sold so far this year, eclipsing the previous annual record of 35, according to investment bank Stifel.

After a busy first half, in which $131.5 billion in biotech deals were completed, deals have slowed in recent months, with only $44.8 billion in deals in the second half to date.

J&J has been among the most active acquirers, striking a $1 billion deal to buy oncology drug developer Firefly Bio earlier this year and a $14.6 billion buyout of psychiatry-focused biotech intracellular therapies early last year.

J&J’s shares are up 38 percent year to date, giving it a market capitalization of nearly $688 billion as of Friday’s close.

An acquisition of Ollin would give J&J a beachhead in drugs to treat retinal diseases, an area in which the pharmaceutical maker has a limited presence despite its large contact lens sales business.

Ollin’s lead drug, OLN324, is expected to be studied in late-stage trials as a treatment for wet age-related macular degeneration and diabetic macular edema, both of which can cause serious vision impairment.

Several major pharmaceutical groups have moved into the eye disease drug business in recent years, with drugmakers like Merck and Bayer buying up early-stage companies. Regeneron’s retinal disease drug Eylea has proven to be one of the most effective blockbuster drugs of all time.

Ollin raised $330 million earlier this year to fund its upcoming Phase 3 trials. Its backers also include biotech venture capital firms TCGX, RA Capital and Monograph Capital.

J&J declined to comment while Ollin did not respond to requests for comment.

Gn bussni

Views: 3
jack colman
Author

jack colman

**Jack** is a staff journalist and digital content writer at **DailyVoxa**, specializing in breaking news, technology, artificial intelligence, business, and global affairs. He is passionate about transforming complex topics into clear, accurate, and engaging stories that help readers stay informed.With a strong focus on fact-based reporting and thorough research, Jack monitors developing events, analyzes reliable sources, and delivers timely news with clarity and context. His work emphasizes accuracy, transparency, and editorial integrity while avoiding sensationalism.At DailyVoxa, every article written by Jack follows the publication's Editorial Policy, Fact-Checking Policy, and Ethics Policy. He is committed to providing trustworthy journalism that empowers readers with reliable information and meaningful insights into the stories shaping the world.

Follow Me
Other Articles
Florida voters are calling for lower property taxes, which could force local governments to rely more on the state.
Previous

Florida voters are calling for lower property taxes, which could force local governments to rely more on the state.

The iPhone 20 Pro might be Apple's least interesting release for the iPhone's 20th anniversary
Next

The iPhone 20 Pro might be Apple’s least interesting release for the iPhone’s 20th anniversary

Deliver fast, factual, and easy-to-understand news covering global events, technology, business, science, AI, health, entertainment, and lifestyle.
  • About Us
  • Accessibility Statement
  • Advertise With Us
  • AI Usage & Transparency Policy
  • Contact us
  • Cookie Policy
  • Corrections Policy
  • Meet Our Team
  • Privacy Policy
    • Disclaimer
    • DMCA & Copyright Policy
    • Editorial Policy
    • Ethics Policy
    • Fact-Checking Policy
  • Terms and Conditions
Copyright 2026 — Today's News. Tomorrow's Perspective.. All rights reserved.